Dutch venture capital/private equity firm Gilde Healthcare held the final close of its latest fund that is opened in April, attracting €740 million ($803 million) from international investors.
Gilde Healthcare Venture&Growth VI fund is focused on fast growing companies developing solutions for better care at lower cost. The new fund will invest €10-70 million per new portfolio company. Including the previous Venture&Growth fund (closed in 2020) and Gilde Healthcare Private Equity IV (closed in 2022), Utrecht, Netherlands-based Gilde Healthcare has raised €1.7 billion in capital over the last three years.
Gilde Healthcare Venture&Growth VI is an Article 9 Fund under the Sustainable Finance Disclosure Regulation (SFDR). The strategy is supported by a dedicated Impact Council, chaired by the former executive director of the European Medicines Agency (EMA).
“Our broad strategy, covering digital health, medtech and therapeutics, results in a holistic approach allowing us to select the most optimal and cost-effective solution for the individual patient,” said Pieter van der Meer, managing partner at Gilde Healthcare, which has €2.6 billion ($2.8 billion) in assets under management. “With a team of sector experts, we help companies to further scale medical innovations and to make them accessible globally.”
Gilde Healthcare invests in companies in Europe and North America active in digital healthcare, medical technology (MedTech) and therapeutics.
One of the firm’s recent investments was in Noema, a clinical stage biopharma company that had a $112 million Series B funding round. Other investments include shoulder replacement implant company Shoulder Innovations and FIRE1, a developer of a remote monitoring solution to improve outcomes for heart failure patients.
